ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Docetaxel

Also written as “docetaxel”, “Taxotere” and “HB1801”.

Its studies are mostly in Breast Neoplasms · Carcinoma, Non-Small-Cell Lung · Prostatic Neoplasms · Stomach Neoplasms · Lung Neoplasms, led by 27 companies.

Drug pageDocetaxel: every studyMany companies study it; this page follows only the 142 they lead. All 1,164 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Jan 18, 2006142 company-led studies, 15 open or runningNext primary completion: Dec 16, 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sanofi540 open or runningphase 4since Jan 18, 2006Nov 1, 1999none ahead
Hoffmann-La Rocheits history only220 open or runningphase 4since Aug 5, 2005Feb 12, 2004none ahead
CSPC Pharmaceutical Groupits history only1511 open or runningphase 3since Apr 20, 2023Mar 10, 2021Dec 16, 2026phase 3 · NCT06747338
Eli Lillyits history only81 open or runningphase 3since Nov 1, 2004Nov 1, 2004May 2027phase 2 · NCT05999994
Pfizerits history only70 open or runningphase 2since Jan 4, 2002Jan 4, 2002none ahead
GlaxoSmithKlineits history only60 open or runningphase 2since Jul 17, 2003Jul 17, 2003none ahead
Amgenits history only40 open or runningphase 2since Jul 5, 2000Jul 5, 2000none ahead
Merckits history only30 open or runningphase 2since Oct 4, 2007Oct 4, 2007none ahead
Novaceaits history only30 open or runningphase 3since Aug 9, 2002Aug 9, 2002none ahead
Novartisits history only20 open or runningphase 3since Jun 29, 2004Jun 29, 2004none ahead

Also a collaborator on its studies: Jazz Pharmaceuticals Ireland, Parexel, Baili-Bio (Chengdu) Pharmaceutical, Clovis Oncology, Astellas Pharma, Exelixis, Gilead Sciences, iTeos Belgium, Intas Pharmaceuticals, Lambda Therapeutic Research, Medigen Biotechnology, US Biotest, Quintiles, MDS Pharma Services, AstraZeneca and Regeneron Pharmaceuticals.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Sanofi only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Nov 1, 1999.

  1. May 29, 2008Phase 3 study in Breast NeoplasmsNCT00688740 · 1,491 enrolled · United States, Argentina, Austria and more
  2. Jun 24, 2008Phase 3 study in Prostatic NeoplasmsNCT00705822 · 54 enrolled · Spain
  3. Jul 24, 2008Phase 2 study in Prostatic NeoplasmsNCT00723086 · 16 enrolled · Japan
  4. Oct 13, 20082 phase 2 studiesNCT00826852, NCT00772863
  5. Oct 13, 2008Phase 4 study in Head and Neck NeoplasmsNCT00772681 · 57 enrolled · Turkey
  6. Dec 18, 2008Phase 3 study in Stomach NeoplasmsNCT00811447 · 243 enrolled · China
  7. Dec 31, 2008Phase 2 study in Stomach NeoplasmsNCT00816543 · 41 enrolled · Korea, Republic of
  8. Jan 7, 2009Phase 2 study in Carcinoma, Non-Small-Cell LungNCT00819728 · 35 enrolled · United States
  9. Jun 5, 2009Phase 2 study in Head and Neck NeoplasmsNCT00916097 · 66 enrolled · Algeria, Morocco, Tunisia
  10. Dec 22, 2009Phase 3 study in Lung NeoplasmsNCT01038661 · 375 enrolled · China
  11. Jun 21, 2010Phase 1 study in NeoplasmsNCT01148615 · 20 enrolled · China
  12. Dec 23, 2010Phase 2 study in Lung NeoplasmsNCT01266512 · 34 enrolled · Hong Kong
  13. Jan 10, 2012Phase 3 study in Stomach NeoplasmsNCT01515748 · 530 enrolled · Korea, Republic of
  14. Oct 29, 2012Phase 2 study in Prostate Cancer MetastaticNCT01718353 · 63 enrolled · United States, Canada

TargetBeta

“Tubulin inhibitor; Tubulin stabiliser”ChEMBL 37, by rule

Other programs on the same 15 targets

ProgramCompanyFurthest phaseStudies
PaclitaxelruleHoffmann-La Rochephase 4202
cabazitaxelruleSanofiphase 421
VinblastineruleTakedaphase 44
desoxyepothilone Brulebeijing-biostar-pharmaceuticals-co-ltdphase 319
plinabulinrulebeyondspring-pharmaceuticals-incphase 38

Studies

All 54 Sanofi leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT01718353Prostate Cancer Metastatic · United States, Canada2CompletedAug 201563
NCT01515748Stomach Neoplasms · Korea, Republic of3CompletedJan 21, 2019530
NCT01266512Lung Neoplasms · Hong Kong2CompletedMar 201434
NCT01148615Neoplasms · China1CompletedSep 201120
NCT01038661Lung Neoplasms · China3CompletedAug 2012375
NCT00916097Head and Neck Neoplasms · Algeria, Morocco, Tunisia2CompletedNov 200566
NCT00819728Carcinoma, Non-Small-Cell Lung · United States2Completed35
NCT00816543Stomach Neoplasms · Korea, Republic of2CompletedMay 201241
NCT00811447Stomach Neoplasms · China3CompletedJun 2012243
NCT00826852Lung Neoplasms · Turkey2CompletedJul 200949
NCT00772863Ovarian Neoplasms · Turkey2CompletedJun 200837
NCT00772681Head and Neck Neoplasms · Turkey4CompletedMar 200857
NCT00723086Prostatic Neoplasms · Japan2CompletedSep 200816
NCT00705822Prostatic Neoplasms · Spain3TerminatedJul 200954
NCT00688740Breast Neoplasms · United States, Argentina, Austria and more3CompletedJan 20101,491
NCT00620100Breast Neoplasms · Austria, Poland2TerminatedApr 20052
NCT00617968Breast Neoplasms · France2Completed5
NCT00565448Nasopharyngeal Neoplasms · Algeria, Brazil, China and more2CompletedMar 200975
NCT00545246Neoplasms · Japan1CompletedJul 201212
NCT00539669Ovarian Neoplasms · Korea, Republic of2Completed47
NCT00539630Carcinoma, Squamous Cell · Korea, Republic of3Completed86
NCT00521521Head and Neck Neoplasms · France2CompletedMay 200686
NCT00514917Prostatic Neoplasms · United States, Belgium, Canada and more3TerminatedSep 2012413
NCT00498797Prostatic Neoplasms · Brazil, Germany, Hungary and more2CompletedJul 200786
NCT00494338Prostatic Neoplasms · Brazil2TerminatedApr 20056
NCT00461344Carcinoma, Ductal2TerminatedJun 200520
NCT00436839Prostatic Neoplasms · China3CompletedJun 2012228
NCT00436293Nasopharyngeal Neoplasms · Hong Kong2CompletedMar 201061
NCT00432315Carcinoma, Squamous Cell · Austria2CompletedOct 200980
NCT00425191Carcinoma, Non-Small-Cell Lung · Italy2CompletedApr 2005165
NCT00424853Carcinoma, Non-Small-Cell Lung · Italy2CompletedAug 200888
NCT00401323Head and Neck Neoplasms · United States, Argentina, Australia and more3CompletedJun 2003568
NCT00382720Stomach Neoplasms · United States, Belgium, France and more2CompletedApr 2010275
NCT00378573Carcinoma, Non-Small-Cell Lung · United States2TerminatedSep 200817
NCT00365365Breast Neoplasms · United States2CompletedOct 2011214
NCT00364611Breast Neoplasms · United States2CompletedJun 201173
NCT00356122Carcinoma, Non-Small-Cell Lung · United States2CompletedAug 201053
NCT00343239Stomach Neoplasms · Turkey2CompletedMar 201259
NCT00312208Breast Neoplasms · United States, Argentina, Australia and more3CompletedOct 20083,299
NCT00296816Ovarian Neoplasms · United States2CompletedAug 2011132
NCT00290966Stomach Neoplasms3Completed610
NCT00283062Prostatic Neoplasms · United States, Australia, Austria and more3CompletedDec 2010228
NCT00280098Prostatic Neoplasms · Czech Republic4CompletedOct 200730
NCT00273546Neoplasms · United States, Argentina, Canada and more3CompletedFeb 2006500
NCT00271323Carcinoma, Non-Small-Cell Lung · France2TerminatedFeb 200714
NCT00268710Prostatic Neoplasms2CompletedMar 2006
NCT00268671Head and Neck Neoplasms2CompletedApr 200645
NCT00263016Carcinoma, Non-Small-Cell Lung · Hong Kong2Terminated50
NCT00258739Lung Neoplasms · Spain2CompletedSep 2007140
NCT00174772Lung Neoplasms · Belgium, Finland, France and more2CompletedFeb 200972
NCT00174629Lung Neoplasms · Germany, Spain, Switzerland3CompletedJan 2007449
NCT00069888Prostatic Neoplasms · United States2CompletedJan 200783
NCT00047840Carcinoma, Non-Small-Cell Lung · United States, Czech Republic, Hungary2Completed129
NCT00002662Breast Neoplasms · United States3Completed

How it is read

Names in the registry

  • “Docetaxel”, 93 entries
  • “docetaxel”, 37 entries
  • “Taxotere”, 9 entries
  • “HB1801”, 8 entries
  • “Docetaxel for injection (Albumin-bound)”, 4 entries

Codes read as this program: CKD810.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.